Bank Julius Baer & Co
AVIR icon

Bank Julius Baer & Co’s Atea Pharmaceuticals AVIR Stock Holding History

Bank Julius Baer & Co’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2,800
Closed -$13K – 586
2022
Q4 		$13K Buy
2,800
+44
+2% +$223 ﹤0.01% 547
2022
Q3 		$16K Sell
2,756
-44
-2% -$337 ﹤0.01% 542
2022
Q2 		$20K Hold
2,800
– – ﹤0.01% 569
2022
Q1 		$20K Buy
+2,800
New +$19K ﹤0.01% 556
2021
Q2 		– Sell
-77,652
Closed -$4.79M – 820
2021
Q1 		$4.79M Buy
+77,652
New +$5.25M 0.04% 204

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank Julius Baer & Co's AVIR Position: Q1 2023 in Review

Bank Julius Baer & Co sold out of Atea Pharmaceuticals (AVIR) in Q1 2023, closing a stake of 2,800 shares — an estimated $13K sold.

Bank Julius Baer & Co first reported a position in AVIR in Q1 2021 and held it in 5 quarters. The position peaked at $4.79M in Q1 2021. 130 funds tracked by Wall St. Rank hold AVIR as of Q1 2023.

  • Bank Julius Baer & Co reported no remaining Atea Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Bank Julius Baer & Co sold 2,800 Atea Pharmaceuticals shares in Q1 2023, an estimated $13K.
  • Bank Julius Baer & Co first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Bank Julius Baer & Co's Atea Pharmaceuticals position peaked at $4.79M in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2023.

Based on Bank Julius Baer & Co's 13F filing for Q1 2023, filed 11 May 2023.